Recent Updates
Recently added Catalysts
IOVA Negative Sentiment Score: 25/100

IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Key Takeaway: Iovance Biotherapeutics is facing a securities class action lawsuit for failing to disclose important information during a specified class period. The lawsuit follows a disappointing financial report where the company reported a significant decline in quarterly revenues and reduced its revenue guidance for the entire fiscal year. Following this announcement, Iovance's stock experienced a sharp decline of nearly 45%. Investors must file lead plaintiff applications by July 15, 2025, to be involved in the lawsuit against the company.

Market Sentiment Analysis

CONCERNS & RISKS

  • Iovance's recent financial results showed a significant decline in product revenue, dropping from $73.7M to $49.3M.
  • The company cut its revenue guidance for the full fiscal year 2025 from $450M-$475M to $250M-$300M.
  • Shares of Iovance dropped 44.8% following the negative financial report, indicating a loss of investor confidence.
  • The lawsuit claims Iovance failed to disclose material information, violating federal securities laws.

Full Press Release Details

NEW ORLEANS, June 04, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Iovance investors should visit us at https://claimsfiler.com/cases/nasdaq-iova/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Iovance and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 8, 2025, the Company announced its 1Q 2025 financial results, disclosing a quarterly total product revenue of $49.3M, a significant decline from the prior quarter’s $73.7M, as well as a 40% cut to its full fiscal year 2025 total product revenue guidance from a range of $450M - $475M to $250M - $300M. Further, the Company revealed it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of Amtagvi and that “[t]he updated forecast considers experience with ATC [authorized treatment center] growth trajectories and treatment timelines for new ATCs.”
On this news, the price of Iovance’s shares fell 44.8%, from $1.42 per share to close at $1.75 per share on May 9, 2025, on unusually heavy trading volume.
The case is Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

The deadline to file lead plaintiff applications is July 15, 2025.

What is the Class Period for the Iovance lawsuit?

The Class Period for the Iovance lawsuit is from May 9, 2024, to May 8, 2025.

Where can I get more information about the lawsuit?

For more information, visit https://claimsfiler.com/cases/nasdaq-iova/.

Why did Iovance's stock price fall dramatically?

Iovance's stock fell 44.8% due to a significant revenue guidance cut announced on May 8, 2025.

Who is handling the Iovance legal case?

The legal case is being handled by Kahn Swick & Foti, LLC.

Last updated: Jun 5, 2025